Leronlimab
Monoclonal antibody used in the treatment of HIV and cancer
Leronlimab (also known as PRO 140) is a humanized monoclonal antibody that targets the CCR5 receptor. It is primarily being investigated for its potential use in the treatment of HIV/AIDS and certain types of cancer.
Mechanism of Action[edit | edit source]
Leronlimab works by binding to the CCR5 receptor, which is a protein on the surface of certain immune cells. The CCR5 receptor is used by the HIV virus to enter and infect host cells. By blocking this receptor, Leronlimab prevents the virus from entering these cells, thereby inhibiting its replication and spread.
In addition to its role in HIV treatment, the CCR5 receptor is also involved in the migration of cancer cells and the immune response to tumors. This has led to research into the use of Leronlimab as a potential treatment for metastatic cancer.
Clinical Trials[edit | edit source]
Leronlimab has undergone several clinical trials to evaluate its safety and efficacy. In HIV treatment, it has been tested as a monotherapy and in combination with other antiretroviral drugs. Results have shown that Leronlimab can significantly reduce viral load in patients with multi-drug resistant HIV.
In cancer research, Leronlimab is being studied for its ability to inhibit metastasis and improve the immune system's response to tumors. Early-phase trials have shown promising results, particularly in patients with triple-negative breast cancer.
Side Effects[edit | edit source]
The most common side effects of Leronlimab include injection site reactions, such as redness and swelling. Other potential side effects may include headache, fatigue, and nausea. As with any investigational drug, the full spectrum of side effects is still being studied.
Regulatory Status[edit | edit source]
As of 2023, Leronlimab is not yet approved by the FDA or other major regulatory bodies. It is currently available through clinical trials and expanded access programs for patients who meet specific criteria.
Also see[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
